Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Curvebeam AI Ltd. ( (AU:CVB) ) just unveiled an update.
CurveBeam AI Limited announced the resignation of Non-Executive Director Ms. Kate Robb due to increased professional commitments. Ms. Robb, who played a pivotal role as Chair of the Audit and Risk Committee during her tenure, is stepping down after contributing significantly to the company’s governance during a key growth period. The board is now actively seeking a replacement with expertise aligned to its strategic initiatives, including a recent joint venture in China and global orthopaedic commercialization. As the company moves forward with these board appointments, it aims to uphold its focus on driving international expansion and strengthening its governance framework.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited (ASX:CVB) is a provider of specialized medical imaging (CT) equipment coupled with AI-enabled SaaS-based clinical assessment solutions designed to enhance the management of musculoskeletal conditions. The company’s flagship product, HiRise™, offers innovative weight-bearing and traditional CT scanning capabilities, setting it apart from conventional CT or MRI devices. With operational hubs in Melbourne, Australia, and Pennsylvania, USA, the company employs over 70 staff and focuses on developing cutting-edge imaging technology globally.
Average Trading Volume: 1,504,028
Technical Sentiment Signal: Sell
Current Market Cap: A$34.15M
Find detailed analytics on CVB stock on TipRanks’ Stock Analysis page.